The Ethics and Governance Office (EGO) includes myself, Joanne Doleman (Research Governance Manager), George Martin (Research Governance Officer) and Catherine McCarthy (Compliance Officer - Nagoya Protocol). We are responsible for advising members of Sanger Institute staff about compliance with the Human Tissue Act, Animals (Scientific Procedures) Act, the Nagoya Protocol and associated Institute policies. We help achieve compliance through the initiation, administration and development of internal processes, and communicate regulatory and policy requirements using a variety of means, including team talks, induction and training sessions, and face-to-face meetings.
We lead on consultation responses for the Institute where national or international proposals for changes to relevant research legislation may impact on our research, or where we wish to join the debate on ethical research practice.
Health Research Authority Trainer on the Human Tissue Act and Course Lead for 'Genetic and Genomic Research - What RECs Should Consider'
Member of EMBL Bioethical Internal Advisory Committee (BIAC)
'Pop-Up' Governance: developing internal governance frameworks for consortia: the example of UK10K.
Life sciences, society and policy 2015;11;10
Sharing and Reuse of Sensitive Data and Samples: Supporting Researchers in Identifying Ethical and Legal Requirements.
Biopreservation and biobanking 2015;13;4;263-70
Managing clinically significant findings in research: the UK10K example.
European journal of human genetics : EJHG 2014;22;9;1100-4
Implementing a successful data-management framework: the UK10K managed access model.
Genome medicine 2013;5;11;100
Baculovirus expression vector system: an emerging host for high-throughput eukaryotic protein expression.
Methods in molecular biology (Clifton, N.J.) 2008;439;269-89
High throughput production of recombinant human proteins for crystallography.
Methods in molecular biology (Clifton, N.J.) 2008;426;221-46
Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.
Antimicrobial agents and chemotherapy 2013;57;12;5977-86
DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity.
Bioorganic & medicinal chemistry letters 2009;19;3;894-9